Oncology Weekly Update Episode 1 by LucidQuest

Oncology Research and Treatment Updates | February 3–9, 2025

Stay up to date with the latest advancements in cancer research, clinical trials, and regulatory approvals. This week’s edition of Oncology Research and Treatment Updates covers new combination therapies, immunotherapy breakthroughs, and FDA approvals that are shaping the future of oncology.

Key Highlights:
???? Radium-223 Combination – Exploring its potential in metastatic prostate cancer
???? Pembrolizumab – Shows benefit in advanced clear cell gynecologic cancer
???? Cabozantinib and Nivolumab – Disease control in microsatellite-stable metastatic colorectal cancer (MSS mCRC)
???? Envafolimab combination – Early efficacy in second-line colorectal cancer
???? 225Ac-Satoreotide – Receives FDA orphan drug status for small cell lung cancer
???? Gemogenovatucel-T – Earns FDA RMAT designation for advanced ovarian cancer
✅ Serplulimab with chemotherapy – Gains EU approval for extensive-stage small cell lung cancer (ES-SCLC)
???? Subcutaneous Amivantamab – Nears EU approval in EGFR-positive non-small cell lung cancer (NSCLC)

Clinical Trial & Research Insights:
???? Radium-223 Combination Therapy – A study at City of Hope evaluates radium-223, hormone therapy, and SBRT to target micrometastatic disease while minimizing long-term side effects.
???? Pembrolizumab in Gynecologic Cancer – A 42 percent disease control rate was observed at 12 weeks, with a median overall survival of 14.8 months.
???? Cabozantinib and Nivolumab in MSS mCRC – A phase 2 trial reports a 40 percent disease control rate, with a median overall survival of 10.9 months.
???? Envafolimab in Colorectal Cancer – Shows a 25 percent objective response rate and 90 percent disease control rate, with no dose-limiting toxicities.
???? 225Ac-Satoreotide for Small Cell Lung Cancer – The upcoming SANTANA-225 trial will evaluate this radiopharmaceutical’s safety and efficacy.
???? Gemogenovatucel-T for Ovarian Cancer – The VITAL trial demonstrated a 92 percent two-year overall survival rate, leading to FDA RMAT designation.
???? Serplulimab for ES-SCLC – Approved in the European Union, based on ASTRUM-005 trial data, showing a median overall survival of 15.4 months.
???? Subcutaneous Amivantamab – A faster, equally effective alternative to intravenous administration, backed by PALOMA-3 trial data.

???? Stay Updated with LucidQuest!

???? Want to stay ahead of the latest cancer research, clinical trials, and oncology insights? Subscribe now for weekly updates from LucidQuest, covering breakthrough treatments, regulatory milestones, and emerging trends.

???? Looking for expert analysis on oncology trends? ???? Visit www.lqventures.com and contact LucidQuest at [email protected] for expert insights.

???? Like, share, and subscribe to stay ahead of the latest in oncology research.

#LucidQuest #Oncology #CancerResearch #ClinicalTrials #ProstateCancer #LungCancer #ColorectalCancer #OvarianCancer #Immunotherapy #FDAApproval #MedicalInnovation ????